Member Info for avctIPmatters

Regrading re-election of Directors - depending on rota rules .

"Directors are subject to re-election at the Annual General Meeting following their appointment. In addition, at each Annual General Meeting one third (or whole number more than one third) of the Directors will retire by rotation."

gmcc

Snapshot answer courtesy : https://x.com/hashtag/AVCT?src=hashtag_click&f=live

Collaborate with a potential patrner on development of another pre|CISION medicine - licence the technology to a potential partner proprietary payload using Avacta technology

.More to come here in the not too distant future .

IP matters - if folks can hold long enough to see the bigger picture.

gmcc

Note : Two major investors increase over 3% .

Lombard - 3.1%

Conifer - 3.1%

Lot of info in full report

https://avacta.com/wp-content/uploads/2025/06/Avacta-Group-Plc-Annual-Report-FINAL.pdf

gmcc

FYI https://avacta.com/investors/corporate-governance/

"This report was approved by the Board of Directors and authorised for issue on 06 June 2025 and was signed on its behalf by:

Shaun Chilton

Chairman

05 June 2025

*This page is updated annually after the publication of the Annual Report & Accounts"

gmcc

FYI https://avacta.com/privacy-policy/ 0 2025-06-06 08:22 +00:00

https://avacta.com/privacy-policy/

gmcc

Good Morning RNS as expected : Hold & wait for me " walk the talk " all about execution -Good luck Avata team

gmcc

"Outlook

2025 and into 2026 are set to be a transformative time for Avacta with multiple catalysts.

For FAP-Dox (AVA6000), we anticipate releasing the initial data in salivary gland cancer in late 2025 and in triple negative breast cancer in H1 2026 from these cohorts. Phase 2 trials in these indications are also planned for H1 2026.

The second asset, FAP-EXd (AVA6103) will advance into clinical testing with the IND filing in late 2025 and initiation of the Phase 1 trial in 2026, with initial data available in late 2026.

Our team continues to explore a number of commercial opportunities. We continue to seek a partner for our lead asset FAP-Dox that is poised to enter Phase 2 in 1H 2026.

Christina Coughlin, Chief Executive Officer "

Today : Think just RNS info on another website page "Update on timing of preliminary results announcement" etc

https://avacta.com/investors

https://avacta.com/investors / 0 2025-06-05 12:35 +00:00

--------------------

incidentally Rob Harrand Head of Data, Systems & IT - left Avacta Decemember 2024.

"Avacta · Full-timeAvacta · Full-time

Jan 2021 - Dec 2024 · 4 yrs"

Anway website not really a priority - Financial plan for the pipeline far more important .

gmcc

Good Morning

https://avacta.com/our-science/

"Precisely

in exact terms; without vagueness: "the guidelines are precisely defined" exactly (used to emphasize the complete accuracy or truth of a statement):"

If not seen before . Perhaps little wonder this X transcript below has merit & believable : The science works .

------------

Courtesy

"Kirsty

@mskirstywirsty

#Biotech #Oncology #Avacta #AVCT #AVA6000 #AVA6103 #PDC #BigPharma #Acquisition #PrecisionMedicine

Avacta’s scalable PDCs, AVA6000 & AVA6103, drive 60-70% acquisition probability by mid-2026. AVA6000 shows 91% DCR in SGC. Also $2.6-6.6B peak sales across 3 indications. AVA6103’s 75x improved therapeutic index targets $5-10B market. Takeover price: $2-5B, per L.E.K. and broker notes."

https://x.com/mskirstywirsty/status/1930473352294215992

Have a nice day

gmcc

Sorry got carried away " riveting" spelling .

gmcc

Change date to Friday for accounts as per RNS also change to corporate-governance ( still badly out of date )-

Very exciting to hear though CO2 Emissions updated for LD & Coris - reveting stuff .

"The increase in Scope 1 CO2e metric tons in 2023 is largely attributable to the inclusion of a full year of emissions data relating to Launch Diagnostics, compared with a shorter two month period post-acquisition in 2022. These emissions are predominantly driven by car fleets of sales representatives and field service engineers. Launch Diagnostics is in the process of phasing out diesel vehicles in favour of hybrid or fully electric vehicles in an effort to reduce its Scope 1 emissions.

The increase in Scope 2 CO2e metric tons in 2023 is again attributable to the inclusion of a full year of emissions dat for Launch Diagnostics, in addition to 7 months of emissions post-acquisition for Coris. In the year, Launch Diagnostics signed a lease for a new more energy efficient premises, with a better EPC rating. The new premises also has electric charging points for vehicles to support the change in car fleet.

In addition, the 2023 emissions data also includes reporting for Coris Bioconcept SRL since its acquisition date. Coris installed solar panels at their premises in Gembloux, Belgium to help minimise non-renewable energy usage."

-------------------

Sitemap Last Modified

https://avacta.com/post-sitemap.xml 2025-06-04 06:14 +00:00

https://avacta.com/page-sitemap.xml 2025-06-04 16:10 +00:00

https://avacta.com/ 0 2025-06-04 16:10 +00:00

https://avacta.com/investors/corporate-governance/ 0 2025-06-04 16:04 +00:00

gmcc

Good Mprning : Coris partners @ SAMIC 2025, which was held on May 31-June 01 at El-Aurassi Hotel, Algiers. Exhibiitng AMR O.K.N.V.I. RESIST-5 Lateral Flow Tests : Pauline Dogné Coris ExportManager on hand to assist :

https://www.linkedin.com/in/pauline-dogn%C3%A9-5382a5140/recent-activity/reactions/

Be interesting to see what Coris actually contribute to Avacta Coffers -seem to have global exposure : LD still offer their products anyway we wait to see who eventually might snap them up & at what price .

https://www.corisbio.com/contact

-------------

Oops not a great start for the new CFO -

gmcc

Good Morning - thanks for sharing :

Very promising clinical data results - Good we own the IP assets -

----------

Avacta science in action courtesy X comments : spreading the word :

Kirsty @mskirstywirsty

·

5h

@Avacta

@Pfizer

@JNJNews

@Novartis

@AbbVie

@Merck

#AVCT #Oncology #Biotech #CancerResearch #PrecisionMedicine #BigPharma #PharmaInnovation

Avacta Therapeutics’ AVA6000 is revolutionizing cancer treatment!

- 100:1 tumor-to-plasma ratio (vs. 8:1 for ADCs) for superior targeting

- FAP-activated prodrug mechanism cuts toxicity

- No lung release, solving ADC’s biggest issue

- Smaller peptides = better penetration + easier manufacturing

#AVCT leading the way!

#AVCT

Kirsty

@mskirstywirsty

·

7h

#avct #Oncology #Biotech #investing

- Superior tumor targeting with a 100:1 tumor-to-plasma ratio (vs. 8:1 for ADCs), enhancing efficacy and reducing toxicity.

- Innovative FAP-activated prodrug mechanism minimizes systemic exposure, addressing toxicity issues of traditional

Show more

Quote

jive_turkey

@jivetur88775834

·

14h

Replying to @RAH00084 and @Blueberrymgmnt

100-to-1 tumour to plasma ratio for ava6k, 8-to-1 for ADCs. #avct

https://x.com/mskirstywirsty/status/1929728533800407276

-----

gmcc

Well we get to listen to Brian Hahn CFO be interesting to hear what he says - Forward guidance on financial plans etc . "preliminary results for year ended December 31, 2024" so already out of date .

Presume the company will continue with the Quarterly business update due end of June so might need to wait a bit longer for any big reveals .

However do agree would be good to get some indication on business progress plans on Wednesday .

We wait & see,

gmcc

Yes i know Avacta not yet developing a cancer drug : never say never .

gmcc

Courtesy of stonks thanks : nice find

https://x.com/JStonker/status/1928487578946154690

@JStonker

#AVCT cited in an extract of 'Our Future Is Biotech' published this afternoon by Money Control - "India's leading financial and business portal".

https://x.com/JStonker/status/1928487578946154690

Liked this bit "Eventually, its technology may be able to develop a simple oral pill for cancer with no side effects, as crazy as that may sound."

gmcc

"

Another British company, Avacta, with a similar technology (although using human proteins rather than anything from a llama or a shark this time) may be able to use that technology to deliver a kind of highly targeted chemotherapy. That is to say that it may be able to manufacture a chemo drug which is released only when it arrives in the tumour microenvironment, thus reducing the horrendous side effects usually associated with chemotherapy very significantly, quite possibly even getting rid of them altogether. Eventually, its technology may be able to develop a simple oral pill for cancer with no side effects, as crazy as that may sound."

Nice to see thanks : Courtesy of https://x.com/42017_13/status/1928454773239398722

"This journal has now been peer reviewed for AVA6103"

"Article

Abstract 3139: The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage

Rink, Curtis ; Clough, Tom ; Watts, Ellen ; Orafidiya, Folake ; Houee, Marine ; Tong, Cindy ; Juskaite, Victoria ; Morrow, Michelle ; Jones, David ; Wilson, Francis

Cancer research (Chicago, Ill.), 2025-04, Vol.85 (8_Supplement_1), p.3139-3139

Peer Reviewed

BrowZine Article Link Icon Read Article "

https://mskcc.primo.exlibrisgroup.com/discovery/fulldisplay?docid=cdi_crossref_primary_10_1158_1538_7445_AM2025_3139&context=PC&vid=01TRII_MSKCC:MSKCC&lang=en&search_scope=MyInst_and_CI&adaptor=Primo%20Central&tab=Everything&query=any,contains,Ava6103&offset=0

This journal has now been peer reviewed for AVA6103

mskcc.primo.exlibrisgroup.com

Abstract 3139: The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which...

AVA6103 is a novel peptide drug conjugate (PDC) based on proprietary pre|CISION® technology which incorporates a dipeptide that is specifically cleaved

gmcc

RNS : mentions reviewing terms + other options ..

"The Board continues to actively explore all available options to finance its clinical therapeutics programs as well as reviewing the terms of the Company's unsecured convertible bond. These include partnering, attracting global specialist biotechnology investors and potentially a NASDAQ dual listing."

gmcc

.

Sounds good Value in in the IP assets .

"HCRx has been helping inventors monetize valuable intellectual property for over a decade. We understand that it can take years to realize the full value of an inventor’s discoveries

HCRx’s platform is designed to help inventors realize a portion of the value created today while also managing the risk associated with the future performance of the commercialized product. In most cases, the structure of a transaction will also allow an inventor to preserve the upside potential of discoveries. Through a royalty monetization, an inventor is able to sell part or all of the future cash flow payments of the royalty contract to HCRx in exchange for a lump sum payment and/or milestone payments."

gmcc

Sounds promising - different way to fund pipeline .

Interesting "REALIZING THE VALUE OF ROYALTIES FOR COMPANIES, INSTITUTIONS AND INVENTORS"

https://www.hcrx.com/approach/royalty-monetization/

gmcc

FYI https://www.linkedin.com/company/coris-bioconcept/posts/

https://samic.dz/

-------------------

"CORIS BIOCONCEPTCORIS BIOCONCEPT

2,903 followers2,903 followers

Visit website

23h • 23 hours ago • Visible to anyone on or off LinkedIn

Follow

📢 Not to be missed this Saturday in Algiers!

Coris BioConcept will participate in the 4th International Congress of the Algerian Society of Clinical Microbiology (SAMiC), this Saturday, May 31, 2025 at 2 p.m., at the El Aurassi Hotel in Algiers 🇩🇿.

🎤 On this occasion, our Export Manager Pauline Dogné will lead a symposium entitled:

"Where to use lateral flow tests to detect antibiotic resistance?"

This is a subject at the heart of global health issues, in the face of the growing urgency of hashtag#AMR.

👨 ⚕️ We will also have the honor of welcoming Prof. BACHTARZI Mohamed Azzedine, head of the central laboratory of the Beni Messous University Hospital in Algiers, who will share his concrete feedback on the use of our tests.

🙏 Thank you to our local partner Expensimed for the invitation.

🔬 Together, let's continue to promote rapid diagnostic solutions for better management of antibiotic resistance.

hashtag#SAMiC2025 hashtag#Alger hashtag#AMR hashtag#RésistanceAntibiotiques hashtag#Microbiologie hashtag#DiagnosticRapide hashtag#SantéPublique hashtag#LateralFlow

gmcc